RYZUMVI
Live / Registered — Registered (as of 26 Nov 2024)
What this means for you
Registered since 26 Nov 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97979106
- Registration number
- 7581889
- Mark type
- Stylized text
- Filed
- 10 Oct 2022
- Published for opposition
- 05 Dec 2023
- Registered
- 26 Nov 2024
- Attorney of record
- Glenn A. Gundersen
Goods and services
- Class 005 — Pharmaceuticals: PHARMACEUTICAL PRODUCTS FOR OPHTHALMOLOGICAL USE; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES AND CONDITIONS
Owner
- OPUS GENETICS, INC., DURHAM, NC, US
- OCUPHIRE PHARMA, INC., Farmington Hills, MI, US
- OCUPHIRE PHARMA, INC., Farmington Hills, MI, US
- OCUPHIRE PHARMA, INC., Farmington Hills, MI, US
Prosecution history
- 26 Feb 2025 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 26 Nov 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 26 Nov 2024 — REGISTERED-PRINCIPAL REGISTER
- 05 Nov 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 05 Nov 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 23 Oct 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 07 May 2024 — USE AMENDMENT FILED
- 23 Oct 2024 — DIVISIONAL PROCESSING COMPLETE
- 23 Oct 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 07 May 2024 — DIVISIONAL REQUEST RECEIVED
- 07 May 2024 — TEAS REQUEST TO DIVIDE RECEIVED
- 30 Jan 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 05 Dec 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 05 Dec 2023 — PUBLISHED FOR OPPOSITION
- 15 Nov 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED